Vivani Medical (Nasdaq:VANI) today announced third-quarter earnings results that included timeline updates on its semaglutide implant. The Alameda, California-based company develops NanoPortal technology, which steadily delivers medication over … [Read More...] about Vivani to initiate study of semaglutide implant in 2026
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
What diabetes tech companies are doing on World Diabetes Day 2025
Once again, World Diabetes Day, celebrated on Nov. 14 every year, has come around, highlighting new initiatives in the diabetes tech space. The date marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with … [Read More...] about What diabetes tech companies are doing on World Diabetes Day 2025
Dexcom unveils new advocates to support World Diabetes Day campaign
Dexcom (NSDQ:DXCM) today announced 16 new advocates representing people with diabetes as part of its World Diabetes Day campaign. Today, Nov. 14, is World Diabetes Day, which marks the birthday of Sir Frederick Banting. Banting discovered the … [Read More...] about Dexcom unveils new advocates to support World Diabetes Day campaign
Renu MedTech introduces tubeless insulin patch pump in India
Renu MedTech today unveiled InsuPatch, its tubeless insulin patch pump designed specifically for advancing diabetes care in India. On LinkedIn, the Pune, India-based company labeled InsuPatch "India's first tubeless, affordable, patch-style … [Read More...] about Renu MedTech introduces tubeless insulin patch pump in India
ViCentra highlights diabetes in the workplace on World Diabetes Day
ViCentra today shared its own employees' stories to highlight diabetes in the workplace on World Diabetes Day. Today, Nov. 14, is World Diabetes Day, which marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along … [Read More...] about ViCentra highlights diabetes in the workplace on World Diabetes Day
Glucotrack now expects spring 2026 FDA IDE submission for implantable CGM
Glucotrack (Nasdaq:GCTK) today announced a slight delay in its plans to submit its long-term glucose monitor to the FDA for IDE. The company said in August that it expected a fourth-quarter investigational device exemption (IDE) submission for the … [Read More...] about Glucotrack now expects spring 2026 FDA IDE submission for implantable CGM
Carrot, Oura, Dexcom partner on biosensor insights for fertility
Carrot announced that it partnered with Oura and Dexcom to deliver actionable, personalized insights supporting fertility goals. The companies came together to provide actionable, personalized insights through the metabolic-fertility program, … [Read More...] about Carrot, Oura, Dexcom partner on biosensor insights for fertility
Vivani to initiate study of semaglutide implant in 2026
Vivani Medical (Nasdaq:VANI) today announced third-quarter earnings results that included timeline updates on its semaglutide implant. The Alameda, California-based company develops NanoPortal technology, which steadily delivers medication over … [Read More...] about Vivani to initiate study of semaglutide implant in 2026
What the launch of Mobi for Android means for Tandem, people with diabetes
This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance … [Read More...] about What the launch of Mobi for Android means for Tandem, people with diabetes
Go-Pen wins CE mark for user-fillable insulin pen
Go-Pen announced today on social media that it received CE mark approval for its user-fillable insulin pen. The Denmark-based company said on LinkedIn that, with CE mark now in hand, adding to FDA clearance achieved in May, it now has the … [Read More...] about Go-Pen wins CE mark for user-fillable insulin pen
Tandem wins FDA nod to pair Mobi pump with Android smartphones
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system … [Read More...] about Tandem wins FDA nod to pair Mobi pump with Android smartphones
In case you missed it
- The top CGM stories of 2025
- Billie Jean King supports Medtronic Diabetes awareness initiative
- Tandem stock rises after hours on Q3 beats, record sales
- Insulet leadership talks patch pump competition, expanding type 2 diabetes market
- Insulet increases guidance again on Q3 beats, 30% sales uptick
- Senseonics posts Q3 sales beat, expects CE mark for Eversense 365 this year
- MIT engineers develop drug delivery patch for post-heart attack healing
- Tandem achieves cybersecurity certification milestone
- 12 things you need to know about the CGM market
- Tidepool, Oura partner on data for diabetes research
- Dexcom leadership addresses G7 issue claims, hopes for expanded CGM coverage
- Modular Medical is seeking CE mark for its next-gen insulin pump
- CGM market report: Significant growth is ahead
- Dexcom stock is down after hours despite Q3 beats, raised sales guidance
- Insulet launches inclusion campaign for Diabetes Awareness Month
Clinical Trials
Vivani to initiate study of semaglutide implant in 2026
Vivani Medical (Nasdaq:VANI) today announced third-quarter earnings results that included timeline updates on its semaglutide implant. The Alameda, California-based company develops NanoPortal technology, which steadily delivers medication over extended periods of time. Vivani aims to guarantee correct patient doses while avoiding potential safety concerns around fluctuating drug release profiles. It can also deliver large hydrophilic […]
Tidepool, Oura partner on data for diabetes research
Tidepool today announced a strategic collaboration with Oura to support a groundbreaking dataset for diabetes research. The initiative between the diabetes software developer and smart ring maker aims to create a comprehensive, multi-modal, real-world dataset for diabetes, utilizing Tidepool’s diabetes device data paired with biometric data collected by the leading Oura Ring Gen 3. This […]
Boston Scientific shares positive Agent drug-coated balloon findings
Boston Scientific (NYSE: BSX) today shared findings from new analyses of its Agent drug-coated balloon (DCB). Agent serves as an alternative to traditional therapies like balloon angioplasty, additional layers of stenting or radiation. The paclitaxel-coated balloon transfers a therapeutic dose of drug to the vessel wall, helping to prevent in-stent restenosis (ISR) reoccurrence. The FDA […]
Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial
Orchestra BioMed (Nasdaq:OBIO) today announced the first patient enrollments in a study of its Virtue Sirolimus AngioInfusion Balloon (SAB). The FDA investigational device exemption (IDE) trial compares the Virtue SAB to the Boston Scientific Agent paclitaxel-coated balloon. Agent is currently the only FDA-approved drug-coated balloon (DCB) for coronary indication, picking up approval in March. New Hope, […]
Multiple studies back Cordis Selution SLR drug-eluting balloon
Cordis today announced new findings from a duo of studies supporting the use of its Selution SLR drug-eluting balloon (DEB) system. Miami Lakes, Florida-based Cordis announced results from the SELUTION DeNovo and SELUTION 4ISR trials at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. Both randomized clinical trials demonstrated positive outcomes that met […]
